Latest news with #MTFBiologics
Yahoo
23-05-2025
- Business
- Yahoo
MTF Biologics and Kolosis BIO introduce allograft tissues for cardiac surgery use
MTF Biologics, in partnership with biologic solutions provider Kolosis BIO, has introduced two new allograft tissues designed to aid cardiac surgeons in complex procedures. The ATLAS Sternal Repair Matrix and the IKON Allograft Surgical Matrix are set to enhance patient outcomes by providing solutions for sternal fusion and soft tissue repair, respectively, particularly in high-risk individuals. Comprising a demineralised cortical bone allograft, ATLAS will be placed between the sternal edges before closure to aid in fusion and stabilisation. It has been processed to retain native growth factors and is evaluated for osteoinductive potential, offering an osteoconductive scaffold that supports quick hydration and bone formation. The IKON Allograft Surgical Matrix aids in incision management and sternal closure. It is designed to minimise bioburden and inflammation while promoting the restoration of blood supply. MTF Biologics noted that this matrix is applied within subcutaneous tissue following a sternal closure and features a collagen structure that supports wound closure in high-risk individuals. MTF Biologics orthopaedic franchise general manager and vice-president Brad Bailey said: "The MTF Biologics team is pleased to apply our proven allografts, developed in collaboration with surgeons across the nation, to transform sternal fusion and wound healing in the cardiac space. "ATLAS and IKON will support clinicians caring for patients with complex challenges who are undergoing high-risk cardiac procedures. The Kolosis BIO team is an ideal partner to bring these innovative solutions to this market with us." Kolosis BIO focuses on commercialising technologies across various verticals in the surgical biologics space. Kolosis BIO CEO Collin Begley said: "For Kolosis, launching ATLAS and IKON in cardiac surgery is an exciting step into a new market, furthering our position as the premier pure-play biologics provider.' "MTF Biologics and Kolosis BIO introduce allograft tissues for cardiac surgery use" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
22-05-2025
- Business
- Yahoo
MTF Biologics and Kolosis BIO Launch Two New Allografts to Advance Cardiac Surgery
ATLAS™ Sternal Repair Matrix is intended for challenging sternal fusion cases and IKON™ Allograft Surgical Matrix assists with soft tissue repair in high-risk patients EDISON, N.J. & SALT LAKE CITY, May 22, 2025--(BUSINESS WIRE)--MTF Biologics, a global nonprofit organization that saves and heals lives by advancing tissue and organ donation, transplantation, and research, and Kolosis BIO (Kolosis), a premier provider of biologic solutions, today announced they have partnered to bring two innovative allograft tissues to cardiac surgeons: ATLAS™ Sternal Repair Matrix for sternal fusion and IKON™ Allograft Surgical Matrix for soft tissue repair in high-risk patients. These high-performance allografts meet critical needs in complex cardiac procedures and will support positive patient outcomes. "The MTF Biologics team is pleased to apply our proven allografts, developed in collaboration with surgeons across the nation, to transform sternal fusion and wound healing in the cardiac space," said Brad Bailey, Vice President and General Manager of MTF Biologics' Orthopedic Franchise. "ATLAS and IKON will support clinicians caring for patients with complex challenges who are undergoing high-risk cardiac procedures. The Kolosis BIO team is an ideal partner to bring these innovative solutions to this market with us." ATLAS Sternal Repair Matrix is a demineralized cortical bone allograft that is inserted between sternal edges prior to closure to support stabilization and fusion in challenging patient cases. Processed to preserve native growth factors and tested for osteoinductive potential, ATLAS offers an osteoconductive scaffold, rapid hydration, and proven bone-forming capacity. IKON Allograft Surgical Matrix is applied within subcutaneous tissue after a sternal closure to support incision closure. IKON processing preserves growth factors and matrix proteins with a cell-friendly collagen structure to support wound closure in high-risk patients. "For Kolosis, launching ATLAS and IKON in cardiac surgery is an exciting step into a new market, furthering our position as the premier pure-play biologics provider," said Collin Begley, CEO of Kolosis BIO. "These advanced allografts redefine standards for sternal repair and soft tissue repair, offering surgeons powerful new tools to improve outcomes." About MTF Biologics MTF Biologics is a global nonprofit organization that saves and heals lives by honoring donated gifts, serving patients and advancing science. It provides unmatched service, resources and expertise to donors and their loved ones who give the gift of donation, people who depend on tissue and organ transplants, healthcare providers and clinicians and scientists. The International Institute for the Advancement of Medicine (IIAM), a Division of MTF Biologics, honors donors of non-transplantable organs by providing their gifts to the medical research community to combat and cure diseases. Statline, also a Division of MTF Biologics, provides specialized screening, coordination, and communications services to organ transplant centers, organ, tissue, and eye procurement organizations, and the hospitals and patients that they serve. Its sister organization, Deutsches Institute for Zell-und Gewebeersatz – DIZG (The German Institute for Cell and Tissue Transplantation) expands its reach to patients across the globe. For more information, please visit About Kolosis BIO Kolosis BIO is a rising biologics pure-play, dedicated to commercializing cutting-edge technologies to multiple verticals in the surgical biologics space. With a proven track record of scaling market-leading technologies, Kolosis is dedicated to driving innovation and pushing the boundaries of science to enhance patient outcomes. With a focus on providing bold technologies and relentless execution, Kolosis has become a leading force in the surgical biologics market. For more information, please visit View source version on Contacts MTF Media Contact:Aleksa Kolosis Media Contact:Maxwell Hunter, COOinfo@ Sign in to access your portfolio
Business Wire
21-05-2025
- Business
- Business Wire
MTF Biologics and Kolosis BIO Launch Two New Allografts to Advance Cardiac Surgery
EDISON, N.J. & SALT LAKE CITY--(BUSINESS WIRE)--MTF Biologics, a global nonprofit organization that saves and heals lives by advancing tissue and organ donation, transplantation, and research, and Kolosis BIO (Kolosis), a premier provider of biologic solutions, today announced they have partnered to bring two innovative allograft tissues to cardiac surgeons: ATLAS ™ Sternal Repair Matrix for sternal fusion and IKON ™ Allogenic Matrix for soft tissue repair in high-risk patients. These high-performance allografts meet critical needs in complex cardiac procedures and will support positive patient outcomes. 'The MTF Biologics team is pleased to apply our proven allografts, developed in collaboration with surgeons across the nation, to transform sternal fusion and wound healing in the cardiac space,' said Brad Bailey, Vice President and General Manager of MTF Biologics' Orthopedic Franchise. 'ATLAS and ICON will support clinicians caring for patients with complex challenges who are undergoing high-risk cardiac procedures. The Kolosis BIO team is an ideal partner to bring these innovative solutions to this market with us.' ATLAS Sternal Repair Matrix is a demineralized cortical bone allograft that is inserted between sternal edges prior to closure to support stabilization and fusion in challenging patient cases. Processed to preserve native growth factors and tested for osteoinductive potential, ATLAS offers an osteoconductive scaffold, rapid hydration, and proven bone-forming capacity. IKON Allogenic Matrix, an allograft matrix, is applied within subcutaneous tissue after a sternal closure to support incision closure. IKON processing preserves growth factors and matrix proteins with a cell-friendly collagen structure to support wound closure in high-risk patients. 'For Kolosis, launching ATLAS and IKON in cardiac surgery is an exciting step into a new market, furthering our position as the premier pure play biologics provider,' said Collin Begley, CEO of Kolosis BIO. 'These advanced allografts redefine standards for sternal repair and soft tissue repair, offering surgeons powerful new tools to improve outcomes.' About MTF Biologics MTF Biologics is a global nonprofit organization that saves and heals lives by honoring donated gifts, serving patients and advancing science. It provides unmatched service, resources and expertise to donors and their loved ones who give the gift of donation, people who depend on tissue and organ transplants, healthcare providers and clinicians and scientists. The International Institute for the Advancement of Medicine (IIAM), a Division of MTF Biologics, honors donors of non-transplantable organs by providing their gifts to the medical research community to combat and cure diseases. Statline, also a Division of MTF Biologics, provides specialized screening, coordination, and communications services to organ transplant centers, organ, tissue, and eye procurement organizations, and the hospitals and patients that they serve. Its sister organization, Deutsches Institute for Zell-und Gewebeersatz – DIZG (The German Institute for Cell and Tissue Transplantation) expands its reach to patients across the globe. About Kolosis BIO Kolosis BIO is a rising biologics pure-play, dedicated to commercializing cutting-edge technologies to multiple verticals in the surgical biologics space. With a proven track record of scaling market-leading technologies, Kolosis is dedicated to driving innovation and pushing the boundaries of science to enhance patient outcomes. With a focus on providing bold technologies and relentless execution, Kolosis has become a leading force in the surgical biologics market. For more information, please visit
Yahoo
21-05-2025
- Business
- Yahoo
MTF Biologics and Kolosis BIO Launch Two New Allografts to Advance Cardiac Surgery
ATLAS ™ Sternal Repair Matrix is intended for challenging sternal fusion cases and IKON ™ Allogenic Matrix assists with soft tissue repair in high-risk patients EDISON, N.J. & SALT LAKE CITY, May 21, 2025--(BUSINESS WIRE)--MTF Biologics, a global nonprofit organization that saves and heals lives by advancing tissue and organ donation, transplantation, and research, and Kolosis BIO (Kolosis), a premier provider of biologic solutions, today announced they have partnered to bring two innovative allograft tissues to cardiac surgeons: ATLAS ™ Sternal Repair Matrix for sternal fusion and IKON ™ Allogenic Matrix for soft tissue repair in high-risk patients. These high-performance allografts meet critical needs in complex cardiac procedures and will support positive patient outcomes. "The MTF Biologics team is pleased to apply our proven allografts, developed in collaboration with surgeons across the nation, to transform sternal fusion and wound healing in the cardiac space," said Brad Bailey, Vice President and General Manager of MTF Biologics' Orthopedic Franchise. "ATLAS and ICON will support clinicians caring for patients with complex challenges who are undergoing high-risk cardiac procedures. The Kolosis BIO team is an ideal partner to bring these innovative solutions to this market with us." ATLAS Sternal Repair Matrix is a demineralized cortical bone allograft that is inserted between sternal edges prior to closure to support stabilization and fusion in challenging patient cases. Processed to preserve native growth factors and tested for osteoinductive potential, ATLAS offers an osteoconductive scaffold, rapid hydration, and proven bone-forming capacity. IKON Allogenic Matrix, an allograft matrix, is applied within subcutaneous tissue after a sternal closure to support incision closure. IKON processing preserves growth factors and matrix proteins with a cell-friendly collagen structure to support wound closure in high-risk patients. "For Kolosis, launching ATLAS and IKON in cardiac surgery is an exciting step into a new market, furthering our position as the premier pure play biologics provider," said Collin Begley, CEO of Kolosis BIO. "These advanced allografts redefine standards for sternal repair and soft tissue repair, offering surgeons powerful new tools to improve outcomes." About MTF Biologics MTF Biologics is a global nonprofit organization that saves and heals lives by honoring donated gifts, serving patients and advancing science. It provides unmatched service, resources and expertise to donors and their loved ones who give the gift of donation, people who depend on tissue and organ transplants, healthcare providers and clinicians and scientists. The International Institute for the Advancement of Medicine (IIAM), a Division of MTF Biologics, honors donors of non-transplantable organs by providing their gifts to the medical research community to combat and cure diseases. Statline, also a Division of MTF Biologics, provides specialized screening, coordination, and communications services to organ transplant centers, organ, tissue, and eye procurement organizations, and the hospitals and patients that they serve. Its sister organization, Deutsches Institute for Zell-und Gewebeersatz – DIZG (The German Institute for Cell and Tissue Transplantation) expands its reach to patients across the globe. About Kolosis BIO Kolosis BIO is a rising biologics pure-play, dedicated to commercializing cutting-edge technologies to multiple verticals in the surgical biologics space. With a proven track record of scaling market-leading technologies, Kolosis is dedicated to driving innovation and pushing the boundaries of science to enhance patient outcomes. With a focus on providing bold technologies and relentless execution, Kolosis has become a leading force in the surgical biologics market. For more information, please visit View source version on Contacts MTF Media Contact:Aleksa Kolosis Media Contact:Maxwell Hunter, COOinfo@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
